Symproic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46375 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Oct, 2026

(3 years from now)

USRE46365 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Jan, 2028

(4 years from now)

US9108975 BDSI Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Nov, 2031

(8 years from now)

US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(9 years from now)

Symproic is owned by Bdsi.

Symproic contains Naldemedine Tosylate.

Symproic has a total of 4 drug patents out of which 0 drug patents have expired.

Symproic was authorised for market use on 23 March, 2017.

Symproic is available in tablet;oral dosage forms.

Symproic can be used as treatment of opioid-induced constipation.

Drug patent challenges can be filed against Symproic from 2021-03-23.

The generics of Symproic are possible to be released after 13 May, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2022

Drugs and Companies using NALDEMEDINE TOSYLATE ingredient

NCE-1 date: 2021-03-23

Market Authorisation Date: 23 March, 2017

Treatment: Treatment of opioid-induced constipation


More Information on Dosage

SYMPROIC family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic